Insmed Insider Sells Shares Worth $4.99mln, SEC Filing Reveals

Insmed Incorporated's CFO sold shares worth $4,985,911, according to a recent SEC filing. The biopharmaceutical company's first commercial product, ARIKAYCE, is used to treat MAC lung disease. Its pipeline includes brensocatib, a treatment for bronchiectasis and other neutrophil-mediated diseases, and TPIP, an inhaled formulation for pulmonary hypertension associated with interstitial lung disease and PAH.